Type 1 diabetes develops when the immune system destroys the pancreatic beta cells responsible for producing insulin. Islet transplantation can restore insulin secretion by introducing healthy insulin-producing cells into a recipient, but transplanted islets are vulnerable to immune rejection and inflammatory damage. Current strategies often rely on immunosuppressive drugs, which can expose patients to infection and other complications, or on semipermeable polymer capsules intended to shield the cells from immune attack. These capsules must be thick enough to provide protection, yet thin enough to permit rapid molecular exchange. That trade-off has made long-term cell survival difficult: thicker barriers can delay the movement of glucose and insulin, while thinner barriers may offer inadequate protection or fail to form consistently around the entire cell cluster.

The new system takes its inspiration from the zona pellucida, a specialized extracellular layer that surrounds mammalian oocytes. During reproduction, this structure provides mechanical protection and participates in highly selective molecular interactions, including the recognition of sperm. Rather than reproducing the zona pellucida’s exact biological composition, the researchers adapted its design principles: a cell-associated layer is assembled through molecular recognition, formed directly at the cell surface and then strengthened into a stable hydrogel. This biomimetic concept is intended to combine the precision of biological recognition with the tunability of synthetic materials.

At the centre of the technique are aptamers, short single-stranded nucleic acid sequences that can be engineered to bind selected molecular targets. In this case, aptamer-directed recognition brings the components needed to construct the capsule into close proximity with the islet surface. Once localized, the components undergo crosslinking, a chemical process that connects individual polymer chains into a three-dimensional network. The resulting hydrogel is then hardened into a coherent coating approximately 20 micrometres thick. Because the capsule is assembled where recognition occurs, rather than being produced around the cells in a separate bulk process, it can form closely around the islet surface and avoid the uneven coverage associated with some conventional encapsulation techniques.

The researchers report a 100 per cent encapsulation efficiency, meaning that every targeted islet received a capsule under the described conditions. The encapsulation was also droplet-free. This is technically important because droplet-based microfluidic and emulsification systems can expose cells to interfaces, shear forces, changes in osmotic conditions or additional processing steps. The new procedure instead takes place in a liquid environment compatible with living cells and does not require harsh factors. According to the study, the islets experienced no detectable loss of viability or function during the encapsulation process, suggesting that the protective coating can be applied without sacrificing the biological performance it is designed to preserve.

The capsule’s thinness is another central feature. A 20-micrometre barrier is substantially thinner than many earlier protective coatings, reducing the distance that glucose must travel to reach beta cells and that insulin must cross after secretion. In principle, shorter diffusion paths can help the encapsulated islets respond more rapidly to changes in blood glucose. The hydrogel must nevertheless remain sufficiently stable to prevent direct contact between donor cells and the recipient’s immune system. The study’s design therefore treats thickness, molecular permeability and structural integrity as interconnected engineering parameters rather than as separate objectives. The researchers’ results indicate that the biomimetic coating achieved this balance well enough to support islet activity after transplantation.

The team tested the encapsulated allogeneic islets in immunocompetent diabetic mice. “Allogeneic” refers to cells transferred between genetically different individuals of the same species, a setting in which immune recognition and rejection remain relevant. “Immunocompetent” mice retain functioning immune systems, making the model more demanding than experiments conducted in animals whose immune responses have been deliberately suppressed or genetically impaired. Following transplantation, the treated animals achieved normoglycaemia, or blood-glucose levels within the normal range. Most maintained normoglycaemia for more than 100 days, indicating that the encapsulated islets continued to release biologically active insulin over an extended period despite being exposed to a functioning host immune system.

The findings suggest that the capsule did more than merely preserve the physical structure of the transplanted islets. To regulate blood glucose, beta cells must sense glucose fluctuations, produce insulin in response and release the hormone in a controlled manner. The maintenance of normoglycaemia implies that the coated islets retained sufficient glucose responsiveness and secretory capacity after transplantation. At the same time, the long duration of glycaemic control suggests that the hydrogel remained in place and continued to provide meaningful protection. The study does not establish that the coating completely eliminates immune recognition, nor does it show that the strategy would work indefinitely, but it demonstrates a sustained therapeutic effect in a stringent preclinical model.

The work also illustrates why cell protection is increasingly being approached as a problem of biological interface design. A capsule placed around a living cell is not simply a passive wall: it must regulate transport, withstand the surrounding tissue environment, avoid damaging the enclosed cells and limit harmful interactions with host biology. By using aptamers to direct assembly at the cell surface, the researchers created a process that resembles biological self-organization more closely than conventional bulk encapsulation. Such molecular precision could eventually be adapted to other cell therapies, including engineered endocrine cells or replacement cells intended to treat diseases beyond diabetes, although each application would require its own safety and compatibility testing.

For patients, the potential significance lies in the possibility of restoring insulin production without continuous systemic immunosuppression. However, the results remain preclinical. Human islets are larger, transplantation procedures are more complex and immune reactions in people can involve both cellular and antibody-mediated mechanisms. Long-term capsule stability, vascularization, inflammation, manufacturing scale-up and the fate of the material after transplantation will all need to be examined. Researchers will also need to determine whether the thin hydrogel can protect cells from the full range of immune and inflammatory threats encountered in the human body. Even so, the study presents a notable advance: a stress-free, droplet-free and molecularly guided method that creates a remarkably thin protective coating while preserving islet function. In diabetic mice with intact immune systems, that coating supported sustained glycaemic control, offering a new direction for the engineering of transplantable living cells.

Subject of Research: Biomimetic hydrogel encapsulation of pancreatic islets for immune protection and sustained blood-glucose regulation in type 1 diabetes.

Article Title: Biomimetic zona pellucida-encapsulated islets for sustained glycaemic control in immunocompetent mice.

Article References: Lee, K., Wang, X., Wen, C. et al. Biomimetic zona pellucida-encapsulated islets for sustained glycaemic control in immunocompetent mice. Nature Biomedical Engineering (2026). https://doi.org/10.1038/s41551-026-01775-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01775-8

Keywords: Islet transplantation, type 1 diabetes, cell encapsulation, hydrogel, aptamers, zona pellucida, biomimetic engineering, immune protection, beta cells, glycaemic control

In a groundbreaking development, researchers from the University of Missouri School of Medicine have pioneered an innovative approach to islet transplantation that circumvents the necessity for chronic immunosuppressive regimens. This novel strategy hinges on the precise bioengineering of donor islets through the covalent attachment of two immune-modulatory molecules: thrombomodulin and CD47. Thrombomodulin, an endothelial cell surface glycoprotein, is known for its anti-inflammatory and anticoagulant properties. It inhibits the activation of the complement cascade and attenuates detrimental inflammatory responses that typically lead to early islet destruction post-transplant. Concurrently, CD47 serves as a “don’t eat me” signal by engaging signal regulatory protein alpha (SIRPα) receptors on macrophages and other immune effector cells, effectively signaling these cells to inhibit phagocytosis and cytotoxic attacks against the graft.

The synergy of thrombomodulin and CD47 integration onto islet surfaces has demonstrated remarkable efficacy in preclinical animal models. The researchers reported that over 72% of recipients transplanted with these co-engineered islets exhibited normalization of blood glucose levels without exogenous insulin administration—a critical milestone indicating functional restoration of endogenous insulin secretion in response to physiological glucose stimuli. This metabolic restoration attests to the bioengineered islets’ ability to maintain glucose sensing and insulin secretory functions, highlighting their clinical potential to transcend the limitations of current insulin therapy regimes.

Significantly, this bioengineering approach offers targeted immune evasion, reducing systemic exposure to immunosuppressive drugs and thereby mitigating associated risks such as nephrotoxicity, hepatotoxicity, and compromised host immunity. By localizing immune modulation to the transplant microenvironment, the transplanted islets evade innate and adaptive immune responses, extending graft survival and functional longevity. The technique exemplifies precision medicine at the cellular interface, leveraging molecular cues to harmonize transplanted tissue with the host immune milieu.

Study lead, Dr. Haval Shirwan, emphasized the transformative promise of this method: “Traditional immunosuppressants systemically weaken the host immune defense, imposing significant side effect burdens. Our approach shields the islets directly, creating a molecular armor that allows transplanted cells to blend seamlessly without evoking immune hostility.” Shirwan’s insights reflect a paradigm shift towards localized immune modulation, which could redefine the therapeutic landscape for autoimmune diseases beyond T1D.

Dr. Esma Yolcu, co-author and principal investigator in pediatric immunology, elaborated on the mechanistic basis: “Thrombomodulin attenuates deleterious inflammation by modulating coagulation and complement pathways, which are key contributors to early graft loss. CD47 operates as a critical immune checkpoint ligand, inhibiting phagocytosis by macrophages and dendritic cells. Together, they synergize to create an immunological ‘cloak’ that significantly boosts islet survival compared to the application of either molecule alone.” These findings underline the necessity of a combinatorial approach in immune engineering for transplant tolerance.

Importantly, the preclinical studies were conducted in allogeneic recipients, a model mimicking the genetic disparity between donor and recipient that typically precipitates transplant rejection. The sustained graft viability and functional insulin output observed in these models, without chronic immunosuppressant administration, forecast promising translational potential. While the experiments utilized animal subjects to establish proof-of-concept, the methodology’s translational trajectory towards human clinical trials is eagerly anticipated.

The implications of this research extend far beyond T1D management. By refining the interface between transplanted tissues and the immune system, this technology paves the way for advancements in bioengineered organ and cell therapies, fundamentally reshaping regenerative medicine. The selective modification of donor cells to skirt immune detection represents an elegant solution to one of transplantation medicine’s most intractable problems—immune rejection—without compromising systemic immune competence.

Currently, approximately 2 million individuals in the United States alone live with T1D, a population that is projected to expand as incidence rates climb globally. The burden of lifelong insulin dependence, frequent glycemic monitoring, and risk of hypoglycemic events underscore the urgent need for innovative disease-modifying therapies. This compelling research underscores the feasibility of developing transplantation-based cures that bypass the systemic toxicities of immunosuppressive drugs, promising enhanced quality of life and reduced long-term complications for patients.

Future studies will need to rigorously evaluate the safety profile and efficacy of this islet-engineering platform in human subjects. Key translational hurdles include scalable manufacturing of engineered islets, ensuring durable expression or retention of immune-regulatory molecules, and comprehensive immunological assessments within human immune systems’ complexity. However, the foundational science detailed in this study constitutes a milestone, demonstrating the concept’s viability and heralding a new dawn in the quest to cure autoimmune diabetes.

The study, titled “Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression,” was published in JCI Insight. It represents a collaborative effort among molecular microbiologists, immunologists, and pediatric researchers who collectively leveraged cutting-edge bioengineering and immunological principles to overcome longstanding obstacles in islet transplantation.

This research exemplifies the confluence of molecular immunology, bioengineering, and clinical innovation, underscoring how understanding and manipulating immune checkpoints and inflammatory cascades at the cellular level can catalyze therapeutic breakthroughs. By harnessing nature’s own regulatory molecules, the investigators have established a promising pathway toward durable islet graft survival, potentially obviating the need for life-altering insulin therapy in T1D.

As this research progresses toward clinical validation, it also opens broader dialogues on tailoring immune evasion mechanisms for a spectrum of cell and tissue transplants, illuminating the future of precision immunotherapy in regenerative medicine. The fusion of molecular engineering and immunomodulation may very well transform autoimmune disease management and organ transplantation, with the promise of restoring physiological function with minimal adverse effects.

Subject of Research: Animals
Article Title: Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression
News Publication Date: 17-Mar-2026
Web References: http://dx.doi.org/10.1172/jci.insight.200686
Keywords: Type 1 diabetes, Islet transplantation, Autoimmune disorders, Pancreas, Islets of Langerhans, Insulin, Immunomodulation, Thrombomodulin, CD47, Immune evasion, Regenerative medicine, Immunosuppressant alternative